Introduction Nowadays tuberculosis (TB) remains a major cause of mortality caused for only one infections agent. This is especially true in developing countries, since 98 % of deaths caused by TB occur in developing areas. In addiction, the World Health Organization estimates that one-third of the population is currently infected with M. tuberculosis in a latent form and risked of developing the active disease [1]. Thus, there is an urgent necessity of studies on mycobacterial metabolism to identify promising targets for the development of new anti-TB agents and new effective vaccines to prevent TB. Cytidine deaminase (CDA) is an evolutionarily conserved enzyme of the pyrimidine salvage pathway and belongs to a family of enzymes that catalyze the irreversible hydrolytic deamination of cytidine and 2 ́deoxycytidine to form uridine and 2 ́-deoxyuridine, respectively [2]. CDA plays an important role in the metabolism of a number of antitumoral and antiviral cytosine nucleoside analogues, leading to their pharmacological inactivation [3]; this fact has increased the interest in developing CDA inhibitors for therapeutic use and attempt to identify potential targets for rational drug and vaccine design.